Wound Management Technologies, Inc Taps Veteran Deborah Jenkins Hutchinson as President to Spearhead Biotech and Healthcare Technology Development

Fort Worth, Texas – (BUSINESS WIRE) – January 12, 2010 - Wound Management Technologies, Inc., (WNDM), has named Deborah Jenkins Hutchison as its new president to help spearhead WNDM’s leveraging of its existing technology and infrastructure to develop opportunities in the rapidly growing markets of biotech and genetic engineering, and to expand WNDM’s technology footprint. WNDM noted that the appointment is extremely timely in light of their upcoming acquisition of Secure eHealth, a technology provider for Wound Care Innovations and for Private Access, an Irvine based innovator in privacy-enhanced search technology who is collaborating with Pfizer and the Genetic Alliance to develop an online community to accelerate clinical research.

Wound Management Technologies Announces Strategic Acquisition of Secure eHealth, LLC to Further Strengthen Its Foothold in the HealthCare Industry

Fort Worth TX., January 11, 2010 – Wound Management Technologies, Inc. (OTCBB: WNDM) announced today that they have reached a mutual understanding and verbal agreement in principle to acquire secure data and messaging provider, Secure eHealth, LLC, and certain other technology assets from VirtualHealth Technologies, Inc. (OTCBB: VHGI). The parties have completed the due diligence process, agreed to the price and terms and are currently drafting and negotiating definitive documentation on this transaction and expect to close the transaction within the next two weeks. In addition to acquiring Secure eHealth, Wound Management will also be acquiring from VHGI all of the intellectual property assets of the real-time prescription drug monitoring company Veriscrip and the Private Access Convertible Note and Agreements. Wound Care Innovations, a WNDM subsidiary, currently licenses the Cifra solution from Secure eHealth and will initially use this highly secure messaging system, document courier and database to share and compile information for ongoing evidence based case studies on its patented collagen CellerateRx® products for treating diabetic wounds.